ZBeats has received U.S. Food and Drug Administration 510(k) clearance for ZBPro Diagnostic v2.0, expanding its independent ECG-analysis platform to support recordings ranging from approximately one minute to as long as 14 days. The clearance, identified by the company as K261580, extends the software across traditional Holter configurations and wearable ECG patches rather than limiting the system to short-duration tracings or one hardware ecosystem. ZBeats plans to showcase the updated platform at HRX Live 2026 in Atlanta.
The significance lies less in the existence of another ECG algorithm and more in the widening duration of ambulatory cardiac data. A standard resting ECG captures only seconds of electrical activity, while intermittent arrhythmias can occur hours or days apart. Extending software analysis across up to two weeks gives clinicians a greater chance of capturing atrial fibrillation, ectopic beats, tachyarrhythmias or other transient abnormalities that may never appear during a short office visit.
Why does monitoring for 14 days change what an ECG system can detect?
Arrhythmias are often episodic. A patient may experience palpitations once every few days while having an entirely normal 12-lead ECG during a clinic appointment.
A longer recording period increases the probability that the abnormal rhythm will occur while the monitor is active.
Traditional Holter monitoring often covers one or two days, although modern devices can record substantially longer. Patch-based systems have expanded that window while making the patient experience more comfortable.
The analytical problem grows as recording length increases. One minute of ECG contains a manageable number of heartbeats. Fourteen days can contain well over a million beats.
Software therefore becomes essential for sorting, classifying and prioritizing events before a physician reviews the study.
ZBPro v2.0 is entering exactly that workflow.
What does hardware-independent ECG analysis mean?
Many cardiac-monitoring systems combine proprietary hardware with proprietary interpretation software. The manufacturer controls both the recording device and the algorithmic workflow.
ZBeats positions ZBPro as an independent analysis layer capable of working with data from multiple recording configurations, including Holters and wearable patches.
That can appeal to diagnostic providers that already own hardware from several suppliers or want to avoid replacing devices simply to adopt different analysis software.
Interoperability can also reduce vendor lock-in.
The challenge is ensuring that the software performs reliably across differences in sampling rate, electrode configuration, signal quality and artifact characteristics among recording devices.
FDA clearance therefore needs to be understood within the specific device-input and intended-use boundaries described in the regulatory documentation, rather than assuming every imaginable ECG source is automatically compatible.
Does ZBPro diagnose arrhythmias autonomously?
ECG analysis software is generally designed to identify and classify candidate events for professional interpretation rather than replace the physician responsible for the final diagnosis.
Algorithms can detect patterns consistent with atrial fibrillation, pauses, tachycardia, bradycardia, premature beats and other abnormalities, but signal artifact can mimic arrhythmia and unusual clinical rhythms can confuse automated classifiers.
Human review remains particularly important when a software-generated result could influence anticoagulation, pacemaker implantation or other major treatment decisions.
The operational value comes from narrowing millions of beats into a manageable set of events requiring attention.
This “AI or automation plus physician” workflow is more realistic than the idea of an algorithm independently managing cardiac patients.
Why are wearable patches changing ambulatory ECG monitoring?
Traditional multi-lead Holter recorders can be effective but may involve wires, electrodes and a recorder that patients find cumbersome.
Adhesive patches can simplify monitoring, reduce interference with ordinary activity and extend recording duration.
Longer wear creates a better opportunity to identify low-burden atrial fibrillation or other intermittent arrhythmias, but it also produces far more data.
That makes software scalability a competitive advantage.
A diagnostic company that can ingest datasets from different patches, identify clinically meaningful events and generate standardized reports can potentially support a high-volume ambulatory-monitoring service without proportionally expanding the number of technicians.
Why is atrial fibrillation an important use case for longer monitoring?
Atrial fibrillation can occur intermittently and without symptoms. Patients may experience short episodes separated by days of normal rhythm.
Detecting AF can have major consequences because certain patients benefit from anticoagulation to reduce stroke risk.
After an unexplained stroke, longer monitoring can also reveal occult AF that was not present during hospital evaluation.
However, more monitoring introduces a new problem: discovering very short episodes whose clinical significance is uncertain.
The ability to detect an arrhythmia does not automatically establish that every episode warrants treatment.
As monitoring becomes increasingly sensitive, clinicians need evidence defining what burden of AF meaningfully changes stroke risk and when anticoagulation produces more benefit than harm.
What does the FDA clearance say about software evolution in cardiac diagnostics?
Medical software is increasingly modular. Hardware captures the physiological signal, while software performs analysis that can be updated more rapidly than the physical recorder.
This creates opportunities for innovation but also requires clear regulatory control.
A software update that changes detection algorithms materially can affect sensitivity, false-positive rates and clinical interpretation.
The FDA 510(k) pathway therefore evaluates whether the new version is substantially equivalent to an appropriate predicate within its intended use.
ZBPro v2.0’s clearance validates the expanded platform for the reviewed use case, not any future algorithm ZBeats may later develop.
Could independent software reduce costs for monitoring providers?
Potentially.
A diagnostic provider often has substantial capital invested in recorders and patches. If analysis software can ingest data from existing hardware, the provider may be able to upgrade interpretation capability without replacing the entire device fleet.
Software centralization can also simplify reporting and technician training.
The economic value depends on licensing cost, workflow efficiency and how much manual review the platform actually reduces.
False positives matter commercially. An algorithm that flags too many benign events can increase technician workload and erase the efficiency benefits of automation.
Real-world performance therefore becomes a major determinant of whether regulatory clearance translates into customer adoption.
What are the limitations of extended ECG monitoring?
Longer recording does not guarantee perfect diagnosis.
Skin irritation can limit patch wear. Electrodes can lose contact, and motion artifact can create noisy segments. Patients may remove devices early, while battery or memory constraints can reduce usable data.
More days also increase incidental findings.
Clinicians may detect brief arrhythmias unrelated to symptoms or prognosis, creating uncertainty rather than clarity.
The best monitoring strategy therefore depends on the clinical question. A patient with daily palpitations may not need two weeks, while someone with infrequent symptoms could benefit substantially from a longer study.
ZBPro’s ability to handle a wide duration range is useful precisely because the same software can potentially support different monitoring strategies.
How does the software fit into the growing remote cardiac-care market?
Cardiology is increasingly moving beyond clinic-based snapshots.
Smartwatches, consumer ECGs, medical patches and implantable monitors create continuous streams of rhythm information. Health systems need infrastructure capable of separating clinically meaningful signals from enormous volumes of normal data.
Independent software platforms can function as the interpretation layer within that ecosystem.
They may also enable smaller monitoring companies or hospitals to combine devices from multiple vendors without maintaining separate analysis workflows for each.
That interoperability can become strategically valuable as wearable hardware commoditizes.
What should cardiology practices watch as ZBPro v2.0 reaches the market?
The first issue is diagnostic performance across different hardware sources and recording durations. Practices should look at sensitivity, specificity and false-positive burden rather than simply whether the software can technically ingest 14 days of data.
The second is workflow integration. Analysis becomes more useful when reports connect smoothly with existing clinical systems and do not create duplicate documentation.
The third is how quickly physicians can review flagged events. A platform that reduces technician time but overwhelms doctors with alerts simply moves the bottleneck downstream.
ZBPro v2.0’s FDA clearance reflects a broader transformation in electrocardiography. The ECG is no longer necessarily a ten-second strip captured in an exam room. It can be a two-week continuous record generated by a patch worn through ordinary life.
The diagnostic challenge has shifted accordingly. Capturing the signal is becoming easier. Turning millions of heartbeats into a concise, reliable clinical answer is increasingly where the value lies.
